my community channel

Novartis has announced that the European Commission has approved Extavia for the treatment of early and relapsing forms of multiple sclerosis. The drug is said to be the first in a new portfolio of medicines from Novartis that is planned to include both established treatments and innovative therapies for patients with multiple sclerosis. Extavia is the Novartis branded version of interferon beta-1b, a first-line disease-modifying therapy injected every other day for the treatment of multiple sclerosis (MS). Formerly known as NVF233, Extavia is the same medicine as Betaferon or Betaseron, which is marketed by Bayer-Schering and was the first beta interferon treatment for MS. Novartis gained rights to its own branded version of this medicine in agreements with Bayer-Schering related to the acquisition of Chiron.................

For the full report please go to MSRC: MS Research News : Drugs : Disease Modifying Drugs : Disease Modifying Drugs Ongoing News : EXTAVIA